The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers
Abstract
This review of the literature aims to identify the acute effects of MDMA (ecstasy) in healthy volunteers. The wide range of relevant but methodologically diverse tests was .rst grouped into clusters to allow an evaluation of tests that would otherwise have been excluded due to their low frequency of utilization. The following three types of tests were evaluated: (1) functional tests quantifying executive, attention, visual, motor, visuomotor and auditory functions, (2) phenomenological tests assessing personal, subjective experiences, and (3) physiological measures re.ecting neurophysiological, endocrine and physiological parameters. MDMA showed robust effects on most of the phenomenological and physiological tests. Functional tests were scarce, preventing any meaningful conclusions to be drawn from their evaluation other than that these tests should be incorporated into future acute-effect studies. A striking doseñresponse relationship appeared for cardiovascular effects. At doses below 1.0 mg/kg MDMA no change was observed relative to placebo while above this dose all studies reported signi.cant increases. Furthermore, pupil size, plasma cortisol and plasma prolactin levels proved responsive to MDMA administration. The reported subjective effects of MDMA matched the entactogenic profile. Although interest in the action of MDMA is considerable, the existing knowledge about the cognitive effects of MDMA in humans is still rather limited and further research into the drug's effects is recommended, also in view of potential therapeutic uses of the drug.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Drug doses were selected based on previous research; MDMA doses in this low-to-moderate range have been safely administered to humans previously, and produce modest to robust alterations in mood state [24].”
From Is Ecstasy an “Empathogen”? Effects of +/- 3,4-Methylenedioxymethamphetamine on Prosocial Feelings and Identification of Emotional States in Others (2010) · cites this paper as [24]
Citations
Cites
A JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Lindemann, L., Jaeschke, G., Michalon, A., Vieira, E., Honer, M., Spooren, W., Porter, R., Hartung, T., Kolczewski, S., Büttelmann, B., et al. (1909) · JAMA · doi:10.1001/jama.1909.02550020033007 · Cited by 7,889
The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”)
Green, A. R., Mechan, A. O., Elliott, J. M., O’Shea, E., & Colado, M. I. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.3.3 · Cited by 1,272
Vollenweider, F. X., Gamma, A., Liechti, M., & Huber, T. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00013-x · Cited by 448
Mas, M., Farré, M., de la Torre, R., Roset, P. N., Segura, J. O., & Camí, J. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)34877-3 · Cited by 362
Gender differences in the subjective effects of MDMA
Liechti, M. E., Gamma, A., & Vollenweider, F. X. (2001) · Psychopharmacology · doi:10.1007/s002130000648 · Cited by 360
Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research
Parrott, A. C. (2001) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.351 · Cited by 337
(±)3,4-Methylenedioxymethamphetamine (‘Ecstasy’)-Induced Serotonin Neurotoxicity: Studies in Animals
Ricaurte, G. A., Yuan, J., & McCann, U. D. (2000) · Neuropsychobiology · doi:10.1159/000026664 · Cited by 292
Reneman, L., Booij, J., de Bruin, K. M., Reitsma, J. B., de Wolff, F. A., Gunning, W. B., den Heeten, G. J., & van den Brink, W. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06888-x · Cited by 252
Liechti, M. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00148-7 · Cited by 248
Liechti, M. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00126-3 · Cited by 245
Liechti, M. E., & Vollenweider, F. X. (2001) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.348 · Cited by 236
Camí, J., Farré, M., Mas, M., Roset, P. N., Poudevida, S., Mas, A., San, L., & de la Torre, R. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200008000-00010 · Cited by 234
Cognitive performance and serotonergic function in users of ecstasy
Verkes, R. J., Gijsman, H. J., Pieters, M. S. M., Schoemaker, R. C., de Visser, S. J., Kuijpers, M., Pennings, E. J. M., de Bruin, D., van de Wijngaart, G. F., van Gerven, J., et al. (2001) · Psychopharmacology · doi:10.1007/s002130000563 · Cited by 233
Self-citationSubjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans
Harris, D. S., Baggott, M., Mendelson, J. H., Mendelson, J. E., & Jones, R. T. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1131-1 · Cited by 229
MDMA (`ecstasy') consumption in the context of polydrug abuse: a report on 150 patients
Schifano, F., Furia, L. D., Forza, G., Minicuci, N., & Bricolo, R. (1998) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(98)00051-9 · Cited by 216
McCann, U. D., Szabó, Z. R., Seckin, E., Rosenblatt, P., Mathews, W. B., Ravert, H. T., Dannals, R. F., & Ricaurte, G. A. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300736 · Cited by 204
LÓPEZ, C. H., Farré, M., Roset, P. N., Menoyo, E., Pizarro, N., Ortuño, J., Torrens, M., Camı́, J., & de la Torre, R. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.1.236 · Cited by 191
A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response
Green, A. R., O’Shea, E., & Colado, M. I. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.07.006 · Cited by 181
Pharmacology of MDMA in Humans
de la Torre, R., Farré, M., Roset, P. N., LÓPEZ, C. H., Más, M., ORTUÑO, J., Menoyo, E., Pizarro, N., Segura, J., & Camı́, J. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb05199.x · Cited by 179
The subjective effects of MDMA and mCPP in moderate MDMA users
Tancer, M. E., & Johanson, C. (2001) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(01)00146-6 · Cited by 179
Frei, E., Gamma, A., Pascual-Marqui, R. D., Lehmann, D., Hell, D., & Vollenweider, F. X. (2001) · Human Brain Mapping · doi:10.1002/hbm.1049 · Cited by 177
Grob, C. S., Poland, R. E., Chang, L., & Ernst, T. (1995) · Behavioural Brain Research · doi:10.1016/0166-4328(96)00078-2 · Cited by 175
Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics
Farré, M., de la Torre, R., Mathúna, B. Ó., Roset, P. N., Peiró, A. M., Torrens, M., Ortuño, J., Pujadas, M., & Camı́, J. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1789-7 · Cited by 165
Gamma, A. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00130-5 · Cited by 162
Tancer, M., & Johanson, C.-E. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(03)00172-8 · Cited by 153
Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function
Colado, M. I., O’Shea, E., & Green, A. R. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1788-8 · Cited by 148
Liechti, M. E., & Vollenweider, F. X. (2000) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(00)00086-9 · Cited by 145
Liechti, M. E., & Vollenweider, F. X. (2000) · Journal of Psychopharmacology · doi:10.1177/026988110001400313 · Cited by 144
Curran, H. V. (2000) · Neuropsychobiology · doi:10.1159/000026668 · Cited by 142
Lester, S. J., Baggott, M. J., Welm, S., Schiller, N. B., Jones, R. T., Foster, E., & Mendelson, J. E. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-12-200012190-00012 · Cited by 138
Serotonergic Neurotoxic Metabolites of Ecstasy Identified in Rat Brain
Jones, D. C., Duvauchelle, C. L., Ikegami, A., Olsen, C. M., Lau, S. S., de la Torre, R., & Monks, T. J. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.077628 · Cited by 126
Biomarkers for the effects of benzodiazepines in healthy volunteers
de Visser, S. J., Post, J. P. V. D., de Waal, P. P., Cornet, F., Cohen, A. F., & van Gerven, J. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.t01-10-01714.x · Cited by 115
Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects
Dumont, G., de Visser, S. J., Cohen, A., & van Gerven, J. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02342.x · Cited by 108
Self-citationEcstasy and Drug Consumption Patterns: A Canadian Rave Population Study
Gross, S., Barrett, S., Shestowsky, J. S., & Pihl, R. (2002) · Canadian journal of psychiatry. Revue canadienne de psychiatrie · doi:10.1177/070674370204700606 · Cited by 106
Lamers, C. T. J., Ramaekers, J. G., Muntjewerff, N. D., Sikkema, K. L., Riedel, W. J., Samyn, N., Read, N., & Brookhuis, K. (2003) · Journal of Psychopharmacology · doi:10.1177/0269881103174015 · Cited by 104
Liechti, M. E. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00199-8 · Cited by 102
Electrophysiological Evidence of Serotonergic Impairment in Long-Term MDMA (“Ecstasy”) Users
Croft, R. J., Klugman, A., Baldeweg, T., & Gruzelier, J. H. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.10.1687 · Cited by 101
Vollenweider, F. X., Remensberger, S., Hell, D., & Geyer, M. A. (1999) · Psychopharmacology · doi:10.1007/s002130050960 · Cited by 97
Acute Psychological and Neurophysiological Effects of MDMA in Humans
Vollenweider, F. X., Liechti, M. E., Gamma, A., Greer, G. R., & Geyer, M. A. (2002) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2002.10399951 · Cited by 89
Biomarkers for the effects of antipsychotic drugs in healthy volunteers
de Visser, S. J., J. van der Post, Pieters, M. S. M., Cohen, A. F., & van Gerven, J. (2001) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2001.01308.x · Cited by 88
Pacifici, R., Zuccaro, P., LÓPEZ, C. H., Pichini, S., Carlo, S. D., Farré, M., Roset, P. N., Ortuño, J., Segura, J., & de la Torre, R. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29682-8 · Cited by 85
Mills, E., Rusyniak, D. E., & Sprague, J. E. (2004) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0591-7 · Cited by 80
Structure‐Activity Relationships of MDMA and Related Compounds: A New Class of Psychoactive Drugs?a
Nichols, D. E., & Oberlender, R. A. (1990) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1990.tb16914.x · Cited by 76
Daumann, J., Fischermann, T., Heekeren, K., Henke, K., Thron, A. K., & Gouzoulis‐Mayfrank, E. (2004) · Psychopharmacology · doi:10.1007/s00213-004-2002-8 · Cited by 76
Tissue concentrations of MDMA and its metabolite MDA in three fatal cases of overdose
García-Repetto, R., Moreno, E., Soriano, T., Jurado, C., Giménez, M. P., & Menéndez‐González, M. (2003) · Forensic Science International · doi:10.1016/s0379-0738(03)00179-8 · Cited by 74
Specific memory deficits in ecstasy users? The results of a meta‐analysis
Verbaten, M. N. (2003) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.482 · Cited by 70
Escobedo, I., O’Shea, E., Orío, L., Sánchez, V., Segura, M., de la Torre, R., Farré, M., Green, A. R., & Colado, M. I. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706071 · Cited by 68
Sánchez, V., O’Shea, E., Saadat, K. S., Elliott, J. M., Colado, M. I., & Green, A. R. (2004) · Journal of Psychopharmacology · doi:10.1177/026988110401800312 · Cited by 67
Immunomodulating properties of MDMA alone and in combination with alcohol: A pilot study
Pacifici, R., Zuccaro, P., Farré, M., Pichini, S., Carlo, S. D., Roset, P. N., Ortuño, J., Segura, J., & de la Torre, R. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00555-x · Cited by 51
Investigating the potential neurotoxicity of Ecstasy (MDMA): an imaging approach
Reneman, L., Booij, J., Majoie, C. B. L. M., van den Brink, W., & den Heeten, G. J. (2001) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.347 · Cited by 51
Brain concentrations of d-MDMA are increased after stress
Johnson, E. A., O'Callaghan, J. P., & Miller, D. B. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1740-3 · Cited by 50
Forsling, M. L., Fallon, J. K., Kicman, A. T., Hutt, A. J., Cowan, D., & Henry, J. A. (2001) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357011777855 · Cited by 48
Mlinar, B., & Corradetti, R. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02884.x · Cited by 43
Immunomodulating Activity of MDMA
Pacifici, R., Zuccaro, P., Farré, M., Pichini, S., Carlo, S. D., Roset, P. N., LÓPEZ, C. H., ORTUÑO, J., Segura, J., Camı́, J., et al. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb05198.x · Cited by 43
Pacifici, R., Pichini, S., Zuccaro, P., Farré, M., Segura, M., Ortuño, J., Carlo, S. D., Bacosi, A., Roset, P. N., Segura, J., et al. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.061374 · Cited by 41
Saldaña, S. N., & Barker, E. L. (2003) · Neuroscience Letters · doi:10.1016/j.neulet.2003.10.032 · Cited by 25
Soar, K., Parrott, A. C., & Fox, H. C. (2004) · Psychological Reports · doi:10.2466/pr0.95.1.192-196 · Cited by 22
Hyperkalemia in fatal MDMA (‘ecstasy’) toxicity
Raviña, P., Quiroga, J., & Raviña, T. (2003) · International Journal of Cardiology · doi:10.1016/s0167-5273(03)00162-1 · Cited by 18
Research works printed but not linked: 2
- Baggott M, 2005, 3,4-Methylenedioxymethamphetamine (MDMA) A Review of the English-Language Scientific and Medical Literature
- 10.1038/sj.npp.1395197 · DOI · Paper page
Cited by
Sorted by citations
Bedi, G., Hyman, D., & de Wit, H. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.08.003 · Cited by 247
Characterizing the cognitive effects of cocaine: a comprehensive review.
Spronk, D. B., van Wel, J. H. P., Ramaekers, J. G., & Verkes, R. J. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.07.003 · Cited by 245
Self-citationDumont, G. J. H., Sweep, F. C. G. J., van der Steen, R., Hermsen, R., Donders, A. R. T., Touw, D. J., van Gerven, J. M. A., Buitelaar, J. K., & Verkes, R. J. (2009) · Social Neuroscience · doi:10.1080/17470910802649470 · Cited by 238
Self-citationSutcliffe, P., Hummel, S., Simpson, E., Young, T., Rees, A., Wilkinson, A., Hamdy, F. C., Clarke, N. W., & Staffurth, J. (2009) · Health Technology Assessment · doi:10.3310/hta13050 · Cited by 237
Effects of MDMA on sociability and neural response to social threat and social reward
Bedi, G., Phan, K. L., Angstadt, M., & de Wit, H. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1635-z · Cited by 206
Metadata
- Authors
- Dumont, G. J. H., & Verkes, R. J.
- Affiliations
- Radboud University Medical Center (NL)
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2006-03
- Volume
- 20
- Issue
- 2
- Pages
- 176-187
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2118539399
- Cited by
- 149
- References
- 58
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 2 · 2023: 7 · 2022: 12 · 2021: 4 · 2020: 5 · 2019: 4 · 2018: 5 · 2017: 6 · 2016: 9 · 2015: 6 · 2014: 14 · 2013: 11 · 2012: 7
- FWCI
- 1.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- MDMA, ecstasy, acute drug effects, healthy volunteers, dose-response relationship, cardiovascular effects, pupil size, plasma cortisol, prolactin, subjective effects, cognitive effects, executive function, attention, motor function, visuomotor function, auditory function
- MeSH terms
- Adolescent, Adult, Affect, Arousal, Brain, Clinical Trials as Topic, Dose-Response Relationship, Drug, Female, Hallucinogens, Humans, Male, Neuropsychological Tests, Reference Values, Serotonin Agents, N-Methyl-3,4-methylenedioxyamphetamine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
